Boji Pharmaceutical: Announcement on the company’s 2025 profit distribution plan
Securities code: 300404 Securities abbreviation: Boji Pharmaceutical Announcement number: 2026-015
Boji Pharmaceutical Technology Co., Ltd.
Announcement on the company’s 2025 profit distribution plan
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions.
1. Review procedure
Boji Pharmaceutical Technology Co., Ltd. (hereinafter referred to as the "Company") held the 20th meeting of the fifth board of directors on April 23, 2026, and reviewed and approved the "Proposal on the Company's Profit Distribution Plan for 2025". The proposal still needs to be submitted to the company's 2025 annual shareholders' meeting for review.
2. Basic information on profit distribution and conversion of capital reserve funds into share capital plan
As audited by Guangdong Sinong Accounting Firm (Special General Partnership), the company's 2025 consolidated statement's net profit attributable to shareholders of the listed company was 30,494,240.60 yuan, and the year-end consolidated statement's cumulative undistributed profit was 228,250,731.77 yuan; the parent company's 2025 net profit was 40,273,284.25 Yuan, the parent company's accumulated undistributed profit at the end of the year was 242,971,328.84 yuan. The company accrues statutory surplus reserve fund based on 10% of the realized net profit.
According to the "Articles of Association" and "Shareholder Return Plan for the Next Three Years (2023-2025)" and other provisions, combined with the company's current overall operation situation and the company's development stage, and on the premise of complying with the company's profit distribution principles and ensuring the company's normal operations and long-term development, the company's 2025 profit distribution plan is formulated as follows:
It is planned to distribute a cash dividend of RMB 0.13 (tax included) to all shareholders for every 10 shares based on the total share capital registered on the equity registration date for equity distribution. No bonus shares will be issued, and no capital reserve will be converted into share capital. The company's current total share capital is 385,863,039 shares, based on which the total cash dividend to be distributed in 2025 is RMB 5,016,219.51 (tax included).
Before the implementation of this profit distribution plan, if the company's total share capital changes, equity distribution will be carried out in accordance with the principle of unchanged distribution ratio, and the total distribution amount will be adjusted accordingly.
3. Details of cash dividend plan
(1) The cash dividend plan does not involve other risk warning situations
Item 2025 2024 Total cash dividends in 2023 (yuan) 5,016,219.51 4,582,401.63 3,802,402.38 Total repurchase and cancellation (yuan) 0 0 0 Net profit attributable to shareholders of listed companies (yuan) 30,494,240.60 28,776,806.52 24,339,436.55 R&D investment (yuan) 57,497,869.16 62,593,951.61 54,970,443.28 Operating income (yuan) 868,644,086.02 742,019,124.54 555,832,418.60 Consolidated statements Accumulated undistributed profits at the end of the year (yuan) 228,250,731.77
Accumulated undistributed profits at the end of the year in the parent company's statement (yuan) 242,971,328.84
Whether the listing has been completed for three complete fiscal years? Yes
Total cumulative cash dividends in the last three fiscal years (yuan) 13,401,023.52
Cumulative total repurchase and write-off in the past three fiscal years (yuan) 0
Average net profit in the last three fiscal years (yuan) 27,870,161.2233
The total amount of cash dividends and repurchases written off in the past three fiscal years
13,401,023.52
(yuan)
Cumulative total R&D investment in the last three fiscal years (yuan) 175,062,264.05
The total cumulative R&D investment in the past three fiscal years accounted for the cumulative operating revenue
8.08%
Proportion of income (%)
Whether it touches Article 9.4 of the GEM Stock Listing Rules
No
Other risk warning situations that may be implemented as specified in item (8)
Other notes:
The company's net profit in 2025 is positive, and the undistributed profits at the end of the consolidated statement and the parent company's statement are both positive. The cumulative cash dividend amount in the last three fiscal years (2023-2025) exceeds 30% of the average annual net profit in the last three fiscal years. It does not trigger other risk warning situations that may be implemented as stipulated in Article 9.4 (8) of the "Shenzhen Stock Exchange GEM Stock Listing Rules".
(2) Reasonable explanation of cash dividend plan
The company's audited trading financial assets, derivative financial assets (except hedging instruments), debt investments, other debt investments, other equity instrument investments, other non-current financial assets, and other current assets (excluding assets related to operating activities such as value-added tax to be deducted, prepaid taxes, contract acquisition costs, etc.) in 2024 and 2025 account for the total accounting and presentation amounts of the financial statement items in the corresponding year's total assets respectively. 12.10% and 11.79%, which do not reach more than 50% of the company's total assets.
This profit distribution plan complies with relevant laws and regulations such as the "Company Law", "Supervisory Guidelines for Listed Companies No. 3 - Cash Dividends of Listed Companies" and the "Articles of Association" and other provisions. It matches the company's operating performance and future development. The total profit distribution does not exceed the profits available for distribution. It is legal, compliant and reasonable, and is conducive to all shareholders sharing the company's operating results.
4. Documents for reference
"Resolution of the 20th Meeting of the Fifth Board of Directors of Boji Pharmaceutical Technology Co., Ltd."
"2025 Audit Report of Boji Pharmaceutical Technology Co., Ltd."
Announcement is hereby made.
Board of Directors of Boji Pharmaceutical Technology Co., Ltd.
April 25, 2026